Haemostasis is the prevention of unwanted blood loss; lean how this process works and is interrupted by blood-clotting and ...

Erythropoiesis-stimulating agents are widely used in patients with cancer; however, uncertainty persists over their effect on survival. This article discusses the results of a meta-analysis of ...

targets in patients receiving erythropoiesis-stimulating agents (ESAs). These recommendations were based on analysis of a systematic review and randomized controlled trials. As one trial published ...

Objectives: Inter-individual variations in sea level performance after altitude training have been attributed, at least in part, to an inter-individual variability in hypoxia induced erythropoiesis.

The Global Renal Anemia Market was valued at approximately USD 2.31 Billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 6.05% over the forecast period from 2024 to 2032 ...

• Acute kidney injury occurs when the kidneys suddenly lose their ability to filter waste from the blood. Erythropoietin-stimulating agents are medicines that are mainly used to treat problems with ...

Erythropoietin (EPO), expressed in red blood progenitor cells, primarily regulates erythropoiesis by binding to its receptor. Besides anemia, recent studies have identified new therapeutic indications ...

Among patients with myelodysplastic syndromes (MDS), treatment with Reblozyl (luspatercept) resulted in at least 12 weeks of ...

An expert discussed the findings of the COMMANDS trial evaluating Reblozyl’s role in red blood cell transfusion independence ...

With a market cap of $2.67 billion, Geron Corporation (GERN) is a small-cap, commercial-stage biopharmaceutical company ...

With FDA approval for imetelstat and solid financials, Geron shows great promise in MDS treatment. Read more on GERN stock ...

Therefore, the researchers suggest discontinuing daprodustat to reduce the risk of recurrent ischemic strokes. Hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors are ...